Sector News

J&J buys into Achillion’s hep C pipeline for up to $1.1B

May 20, 2015
Life sciences
Johnson & Johnson, fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals’ pipeline of antiviral treatments.
 
Under the deal, J&J is making a $225 million investment in its partner and promising up to $905 million in milestone payments in order to get its hands on a group of in-development hep C treatments. The plan is to develop Achillion’s drugs in combination with one another and, ideally, come up with a regimen that can cure the infection in as few as four weeks. Leading the pipeline is ACH-3102, Achillion’s Phase II NS5A inhibitor, followed by the complementary ACH-3422 and sovaprevir.
 
For J&J, the three assets present another set of potential shots on goal as it works to catch up with Gilead Sciences and AbbVie in the field of next-gen hep C treatments. The company markets Olysio alongside partner Medivir but has struggled to compete with the all-oral cures that now dominate the market.
 
Eyeing down-the-line success, J&J spent $1.75 billion on Alios BioPharma last year to pick up some early-stage nucleotide analogs, and its latest deal with Achillion is designed to further widen the company’s antiviral pipeline.
 
For Achillion, however, the agreement falls short of what many investors had hoped to see come of the biotech’s assets. Under the deal, the Connecticut drug developer is handing over worldwide rights to its top prospects in exchange for equity, not upfront cash, holding on to a royalty percentage between the mid-teens and low-twenties, depending on future sales.
 
In February, Achillion reported that a combination of ACH-3102 and Gilead’s blockbuster Sovaldi notched a 100% cure rate after 6 weeks in a 12-patient study, sending the biotech’s shares skyward and stoking hopes that it might be a major takeout target. In the end Achillion’s investors–some of whom had openly hoped Gilead might step in and acquire the company at a steep premium–were disappointed with the terms of the J&J deal, sending the biotech’s shares down about 5% after hours on Tuesday.
 
But CEO Milind Deshpande contends the new agreement is a win-win. Putting its assets in the hands of J&J’s storied Janssen unit gives them the best chance of success, Deshpande said, while the equity investment will allow Achillion to accelerate its preclinical work on drugs that target the complement pathway.
 
Meanwhile, Gilead and AbbVie are raking in billions with their combo hep C treatments. Behind them, a cadre of contenders including Merck and Bristol-Myers Squibb is developing new regimens that promise to rid more patients of the virus at a faster clip, angling for the top spot in a blockbuster market.
 
By Damian Garde
 

comments closed

Related News

March 2, 2024

Seeking blockbuster status, UCB eyes 4 new indications for psoriasis med Bimzelx in 2024

Life sciences

After 14 regulatory approvals on three continents last year, UCB is positioned to grow for “a decade-plus,” CEO Jean-Christophe Tellier said in the company’s full-year earnings press release. Meanwhile, eight regulatory reviews are ongoing.

March 2, 2024

Argenx goes again, ramping up unbranded campaign ahead of hoped-for label expansion

Life sciences

Vyvgart Hytrulo, the subcutaneous version of argenx’s FcRn blocker, is already approved in generalized myasthenia gravis (gMG). Supported by data published last year, the biotech has filed for approval in a second setting, chronic inflammatory demyelinating polyneuropathy (CIDP), and is now counting down the weeks until the FDA rules on its submission.

March 2, 2024

EuroAPI appoints new CEO and lays out restructuring plan as manufacturer’s losses mount

Life sciences

Overseeing the four-year plan, dubbed FOCUS-27, will be new chief executive officer Ludwig de Mot—an industry veteran with a track record at “companies undergoing transformation,” EuroAPI said in an earnings release Wednesday. De Mot, who will take up the reins on Friday, joined the company in January as EuroAPI’s chief transformation officer.

How can we help you?

We're easy to reach